William Copalu

519 total citations
16 papers, 403 citations indexed

About

William Copalu is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, William Copalu has authored 16 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in William Copalu's work include Cancer Treatment and Pharmacology (8 papers), HER2/EGFR in Cancer Research (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). William Copalu is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), HER2/EGFR in Cancer Research (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). William Copalu collaborates with scholars based in United Kingdom, Netherlands and United States. William Copalu's co-authors include Jan H.M. Schellens, Jos H. Beijnen, J. Wanders, James P. O’Brien, Antonina Joanna Mazur, David S. Boss, Hilary Glen, T.R. Jeffry Evans, R.S. Morrison and Alwin D. R. Huitema and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

William Copalu

16 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Copalu United Kingdom	12	174	115	84	73	53	16	403
Matthew Hoffmann United States	13	118 0.7×	206 1.8×	60 0.7×	71 1.0×	38 0.7×	39	519
Qianzhou Lv China	13	54 0.3×	112 1.0×	35 0.4×	75 1.0×	94 1.8×	41	428
Feng Bai United States	11	235 1.4×	211 1.8×	126 1.5×	23 0.3×	25 0.5×	19	527
Hyun-Jung Cho South Korea	12	128 0.7×	129 1.1×	32 0.4×	33 0.5×	48 0.9×	25	493
Koen G. A. M. Hussaarts Netherlands	9	122 0.7×	100 0.9×	125 1.5×	19 0.3×	20 0.4×	14	343
Femke M. de Man Netherlands	10	245 1.4×	219 1.9×	96 1.1×	30 0.4×	33 0.6×	19	539
Rongyue Teng United States	18	157 0.9×	236 2.1×	56 0.7×	210 2.9×	179 3.4×	37	848
Jin Ah Jung South Korea	11	100 0.6×	85 0.7×	21 0.3×	72 1.0×	48 0.9×	49	409
Sherri Patterson United States	9	233 1.3×	148 1.3×	72 0.9×	69 0.9×	15 0.3×	12	504
Bas Thijssen Netherlands	12	205 1.2×	138 1.2×	70 0.8×	55 0.8×	41 0.8×	21	461

Countries citing papers authored by William Copalu

Since Specialization

Citations

This map shows the geographic impact of William Copalu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Copalu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Copalu more than expected).

Fields of papers citing papers by William Copalu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Copalu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Copalu. The network helps show where William Copalu may publish in the future.

Co-authorship network of co-authors of William Copalu

This figure shows the co-authorship network connecting the top 25 collaborators of William Copalu. A scholar is included among the top collaborators of William Copalu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Copalu. William Copalu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Patel, Munjal, Francesco Bellanti, David W. Hilbert, et al.. (2021). Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia. Clinical and Translational Science. 15(2). 396–408. 18 indexed citations

Patel, Parul, Mallika Lala, Kenny J. Watson, et al.. (2019). Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections. CPT Pharmacometrics & Systems Pharmacology. 8(10). 748–758. 45 indexed citations

Devriese, Lot A., Marja Mergui‐Roelvink, J. Wanders, et al.. (2012). Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Investigational New Drugs. 31(2). 381–389. 21 indexed citations

Boss, David S., Hilary Glen, Jos H. Beijnen, et al.. (2012). A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 106(10). 1598–1604. 150 indexed citations

Guffon, Nathalie, et al.. (2012). Developing a new formulation of sodium phenylbutyrate. Archives of Disease in Childhood. 97(12). 1081–1085. 29 indexed citations

Devriese, Lot A., Petronella O. Witteveen, J. Wanders, et al.. (2012). Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. British Journal of Clinical Pharmacology. 75(2). 507–521. 16 indexed citations

Dubbelman, Anne-Charlotte, Hilde Rosing, Bram Thijssen, et al.. (2011). Validation of high-performance liquid chromatography–tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. Journal of Chromatography B. 879(15-16). 1149–1155. 9 indexed citations

Wanders, J., G. Edwards, Larisa Reyderman, et al.. (2010). 574 Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET). European Journal of Cancer Supplements. 8(7). 181–181. 6 indexed citations

Marchetti, Silvia, Marja Mergui‐Roelvink, Larisa Reyderman, et al.. (2010). Eribulin mesylate pharmacokinetics in patients with hepatic impairment.. Journal of Clinical Oncology. 28(15_suppl). 2582–2582. 17 indexed citations

10.

Zandvliet, Anthe S., Mats O. Karlsson, Jan H.M. Schellens, et al.. (2009). Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Investigational New Drugs. 28(1). 61–75. 13 indexed citations

11.

Zandvliet, Anthe S., Jan H.M. Schellens, William Copalu, Jos H. Beijnen, & Alwin D. R. Huitema. (2009). Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. Journal of Pharmacokinetics and Pharmacodynamics. 36(1). 39–62. 7 indexed citations

12.

Beijnen, JH, et al.. (2007). PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression. Clinical Pharmacology & Therapeutics. 83(6). 829–839. 23 indexed citations

13.

Glen, Hilary, David S. Boss, T. R. J. Evans, et al.. (2007). A phase I dose finding study of E7080 in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 25(18_suppl). 14073–14073. 7 indexed citations

14.

Zandvliet, Anthe S., Alwin D. R. Huitema, William Copalu, et al.. (2007). CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity. Clinical Cancer Research. 13(10). 2970–2976. 20 indexed citations

15.

Zandvliet, Anthe S., William Copalu, Jan H.M. Schellens, Jos H. Beijnen, & Alwin D. R. Huitema. (2006). SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES. Drug Metabolism and Disposition. 34(6). 1041–1046. 11 indexed citations

16.

Zandvliet, Anthe S., Jan H.M. Schellens, William Copalu, Jos H. Beijnen, & Alwin D. R. Huitema. (2006). A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam. Journal of Pharmacokinetics and Pharmacodynamics. 33(5). 543–570. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact